Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non-Current Debt (2021 - 2025)

Arcutis Biotherapeutics has reported Non-Current Debt over the past 5 years, most recently at $108.0 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $108.0 million for Q4 2025, up 0.71% from a year ago — trailing twelve months through Dec 2025 was $108.0 million (up 0.71% YoY), and the annual figure for FY2025 was $108.0 million, up 0.71%.
  • Non-Current Debt for Q4 2025 was $108.0 million at Arcutis Biotherapeutics, roughly flat from $107.5 million in the prior quarter.
  • Over the last five years, Non-Current Debt for ARQT hit a ceiling of $203.8 million in Q2 2024 and a floor of $72.4 million in Q4 2021.
  • Median Non-Current Debt over the past 5 years was $108.0 million (2025), compared with a mean of $144.9 million.
  • Biggest five-year swings in Non-Current Debt: soared 173.35% in 2022 and later plummeted 47.66% in 2024.
  • Arcutis Biotherapeutics' Non-Current Debt stood at $72.4 million in 2021, then soared by 173.35% to $197.8 million in 2022, then grew by 2.04% to $201.8 million in 2023, then crashed by 46.88% to $107.2 million in 2024, then increased by 0.71% to $108.0 million in 2025.
  • The last three reported values for Non-Current Debt were $108.0 million (Q4 2025), $107.5 million (Q3 2025), and $107.0 million (Q2 2025) per Business Quant data.